Defense World
21 Mar 2026, 06:34 UTC · 35w ago
Taysha Gene Therapies Q4 Earnings Call Highlights
Impact · against what's priced in
The clinical progress of TSHA-102 provides a positive fundamental driver, though this is partially tempered by increasing operational costs. The net effect is a modest positive move as pivotal trial execution remains the primary valuation catalyst.
- TSHA+0.20
No priced-in read yet
- In context
FDA alignment and the commencement of the pivotal trial for TSHA-102 are positive milestones, though they are offset by higher operating expenses and a wider net loss for 2025.
Read from the article alone

Top 1 mover · tap to explore




